ICH-话题@MedSci

#ICH#

62篇内容 | 1406人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1316372, encodeId=b1c313163e28f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调，获得FDA孤儿药称号, objectType=article, longId=181655, objectId=22581816559a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22581816559a, replyNumber=0, likeNumber=60, createdTime=2019-10-22, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22581816559a, moduleTitle=Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调，获得FDA孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22581816559a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316371, encodeId=3c3013163e182, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查, objectType=article, longId=181535, objectId=7549181535e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7549181535e0, replyNumber=0, likeNumber=45, createdTime=2019-10-20, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7549181535e0, moduleTitle=AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7549181535e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316370, encodeId=834d13163e017, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Daiichi Sankyo的Turalio成为FDA批准的腱鞘巨细胞瘤治疗药物, objectType=article, longId=176954, objectId=78dc1e695499, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78dc1e695499, replyNumber=0, likeNumber=38, createdTime=2019-08-07, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78dc1e695499, moduleTitle=Daiichi Sankyo的Turalio成为FDA批准的腱鞘巨细胞瘤治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78dc1e695499)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316369, encodeId=1ee713163692b, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=FDA授予OTL-103再生医学高级治疗（RMAT）认定用于治疗Wiskott-Aldrich综合征, objectType=article, longId=176838, objectId=82c81e6838d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c81e6838d9, replyNumber=0, likeNumber=37, createdTime=2019-08-06, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c81e6838d9, moduleTitle=FDA授予OTL-103再生医学高级治疗（RMAT）认定用于治疗Wiskott-Aldrich综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c81e6838d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316368, encodeId=17f0131636838, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=ICH-Q7a（中英文对照稿）——FDA 原料药GMP 指南, objectType=article, longId=172269, objectId=41b11e2269ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41b11e2269ab, replyNumber=0, likeNumber=58, createdTime=2019-06-28, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41b11e2269ab, moduleTitle=ICH-Q7a（中英文对照稿）——FDA 原料药GMP 指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41b11e2269ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316367, encodeId=5b38131636e49, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=ICH-Q2中文稿, objectType=article, longId=172266, objectId=43361e2266db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43361e2266db, replyNumber=0, likeNumber=27, createdTime=2019-06-28, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43361e2266db, moduleTitle=ICH-Q2中文稿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43361e2266db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316366, encodeId=c87213163666a, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, objectType=article, longId=164438, objectId=87fe1644385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fe1644385f, replyNumber=0, likeNumber=22, createdTime=2019-04-18, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fe1644385f, moduleTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fe1644385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316365, encodeId=4e251316365df, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, objectType=article, longId=163986, objectId=5b4b163986c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4b163986c0, replyNumber=0, likeNumber=34, createdTime=2019-04-11, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4b163986c0, moduleTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4b163986c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316364, encodeId=748c1316364bb, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Neurology：深部+皮层 ICH/微出血的病因是什么？, objectType=article, longId=163256, objectId=8820163256bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8820163256bc, replyNumber=0, likeNumber=16, createdTime=2019-03-31, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8820163256bc, moduleTitle=Neurology：深部+皮层 ICH/微出血的病因是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8820163256bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316363, encodeId=3f2f1316363d1, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Blood：多发性骨髓瘤影像学检查：Which? When?, objectType=article, longId=159867, objectId=d86715986ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d86715986ecf, replyNumber=0, likeNumber=45, createdTime=2019-02-14, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d86715986ecf, moduleTitle=Blood：多发性骨髓瘤影像学检查：Which? When?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d86715986ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316362, encodeId=02811316362f8, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Daiichi宣布开展临床试验：评价其在研抗体偶联药物和Keytruda联合治疗乳腺癌和肺癌的药效, objectType=article, longId=149488, objectId=4ea8149488e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea8149488e4, replyNumber=0, likeNumber=23, createdTime=2018-09-25, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea8149488e4, moduleTitle=Daiichi宣布开展临床试验：评价其在研抗体偶联药物和Keytruda联合治疗乳腺癌和肺癌的药效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea8149488e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316361, encodeId=326513163610d, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Blood：MiR-125a和miR-34a可预测CLL患者是否发生Richter综合征, objectType=article, longId=149386, objectId=f4661493864f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4661493864f, replyNumber=0, likeNumber=28, createdTime=2018-09-24, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4661493864f, moduleTitle=Blood：MiR-125a和miR-34a可预测CLL患者是否发生Richter综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4661493864f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316360, encodeId=e284131636040, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=加入ICH后又一指导原则向社会征求意见, objectType=article, longId=148616, objectId=24bb14861674, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24bb14861674, replyNumber=0, likeNumber=45, createdTime=2018-09-12, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24bb14861674, moduleTitle=加入ICH后又一指导原则向社会征求意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24bb14861674)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316359, encodeId=be6a1316359f4, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Strabismus：Michael Constantine Psellus和他对斜视的定义, objectType=article, longId=147269, objectId=336314e26909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=336314e26909, replyNumber=0, likeNumber=37, createdTime=2018-08-24, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=336314e26909, moduleTitle=Strabismus：Michael Constantine Psellus和他对斜视的定义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=336314e26909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316358, encodeId=73de1316358c1, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Stroke：DVT/PE：DOACs的优越性再添一项 ICH显著降低, objectType=article, longId=146146, objectId=d0a51461468c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0a51461468c, replyNumber=0, likeNumber=34, createdTime=2018-08-10, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0a51461468c, moduleTitle=Stroke：DVT/PE：DOACs的优越性再添一项 ICH显著降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0a51461468c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316357, encodeId=72ea131635e8f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=ICH将如何影响中国制药, objectType=article, longId=140704, objectId=94b9140e048b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b9140e048b, replyNumber=0, likeNumber=31, createdTime=2018-06-15, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b9140e048b, moduleTitle=ICH将如何影响中国制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b9140e048b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316356, encodeId=ad7c1316356f8, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=国家药品监督管理局当选ICH管理委员会成员, objectType=article, longId=140342, objectId=fc22140342a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc22140342a0, replyNumber=0, likeNumber=36, createdTime=2018-06-10, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc22140342a0, moduleTitle=国家药品监督管理局当选ICH管理委员会成员, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc22140342a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316355, encodeId=c0fc13163552f, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=J Dent Res：基于Thiol-Michael光聚合的牙科修复材料, objectType=article, longId=138440, objectId=5839138440a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5839138440a5, replyNumber=0, likeNumber=29, createdTime=2018-05-19, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5839138440a5, moduleTitle=J Dent Res：基于Thiol-Michael光聚合的牙科修复材料, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5839138440a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316354, encodeId=92a3131635462, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Blood：Richter综合征的生物学特性和治疗进展, objectType=article, longId=136585, objectId=4a4813658597, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4813658597, replyNumber=0, likeNumber=27, createdTime=2018-04-28, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4813658597, moduleTitle=Blood：Richter综合征的生物学特性和治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4813658597)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1316353, encodeId=038d131635343, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, objectTitle=Ocaliva（obeticholic acid）：添加黑框警告为突出显示正确的剂量, objectType=article, longId=128825, objectId=9daf12882542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9daf12882542, replyNumber=0, likeNumber=25, createdTime=2018-02-06, rootId=0, userName=diushouji, userId=c192448, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9daf12882542, moduleTitle=Ocaliva（obeticholic acid）：添加黑框警告为突出显示正确的剂量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9daf12882542)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ICH

2020-05-29

diushouji (审核中...)

前往app查看评论内容

#ICH#

Minoryx公司的PPRP激动剂来瑞格列酮治疗Friedreich共济失调，获得FDA孤儿药称号

2019-10-22

diushouji (审核中...)

前往app查看评论内容

#ICH#

AZ/Daiichi的乳腺癌曲妥珠抗体偶联药物ADC获得美国优先审查

2019-10-20

diushouji (审核中...)

前往app查看评论内容

#ICH#

Daiichi Sankyo的Turalio成为FDA批准的腱鞘巨细胞瘤治疗药物

2019-08-07

diushouji (审核中...)

前往app查看评论内容

#ICH#

FDA授予OTL-103再生医学高级治疗（RMAT）认定用于治疗Wiskott-Aldrich综合征

2019-08-06

diushouji (审核中...)

前往app查看评论内容

#ICH#

ICH-Q7a（中英文对照稿）——FDA 原料药GMP 指南

2019-06-28

diushouji (审核中...)

前往app查看评论内容

#ICH#

ICH-Q2中文稿

2019-06-28

diushouji (审核中...)

前往app查看评论内容

#ICH#

Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估

2019-04-18

diushouji (审核中...)

前往app查看评论内容

#ICH#

Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤

2019-04-11

diushouji (审核中...)

前往app查看评论内容

#ICH#

Neurology：深部+皮层 ICH/微出血的病因是什么？

2019-03-31

diushouji (审核中...)

前往app查看评论内容

#ICH#

Blood：多发性骨髓瘤影像学检查：Which? When?

2019-02-14

diushouji (审核中...)

前往app查看评论内容

#ICH#

Daiichi宣布开展临床试验：评价其在研抗体偶联药物和Keytruda联合治疗乳腺癌和肺癌的药效

2018-09-25

diushouji (审核中...)

前往app查看评论内容

#ICH#

Blood：MiR-125a和miR-34a可预测CLL患者是否发生Richter综合征

2018-09-24

diushouji (审核中...)

前往app查看评论内容

#ICH#

加入ICH后又一指导原则向社会征求意见

2018-09-12

diushouji (审核中...)

前往app查看评论内容

#ICH#

Strabismus：Michael Constantine Psellus和他对斜视的定义

2018-08-24

diushouji (审核中...)

前往app查看评论内容

#ICH#

Stroke：DVT/PE：DOACs的优越性再添一项 ICH显著降低

2018-08-10

diushouji (审核中...)

前往app查看评论内容

#ICH#

ICH将如何影响中国制药

2018-06-15

diushouji (审核中...)

前往app查看评论内容

#ICH#

国家药品监督管理局当选ICH管理委员会成员

2018-06-10

diushouji (审核中...)

前往app查看评论内容

#ICH#

J Dent Res：基于Thiol-Michael光聚合的牙科修复材料

2018-05-19

diushouji (审核中...)

前往app查看评论内容

#ICH#

Blood：Richter综合征的生物学特性和治疗进展

2018-04-28

diushouji (审核中...)

前往app查看评论内容

#ICH#

Ocaliva（obeticholic acid）：添加黑框警告为突出显示正确的剂量

2018-02-06

科室
- - 订阅+
  - 更多科室
工具
服务